CD8A and cancer: DNAM-1 + CD8+ tumor-infiltrating T cells possess greater self-renewal ability and cytotoxicity, and DNAM-1 agonist antibody-mediated activation of DNAM-1 augments the effect of TIGIT blockade on CD8 T-cell responses and increases the number of DNAM-1 CD8 T cells, which improves responses to anti-TIGIT therapy for cancer immunotherapy [31].